Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,205 cases.

Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,147 cases.

IPC Councilor, Luigi Naldi, MD, shares his expert opinion on a population-based study of COVID-19 - associated hospitalization and mortality in patients with psoriasis.

Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,118 cases.

The review is up-to-date and discusses the current knowledge and challenges in managing psoriasis during the SARS-CoV-2 pandemic and nicely points out future directions of psoriasis research by highlighting unresolved questions, new developments, and unmet medical needs.

Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.

Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases.

Professor Francesca Capon provides a commentary An article recently published in the Journal of Allergy and Clinical Immunology1 suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%.

Held virtually on December 11 due to the Coronavirus Pandemic, the 2020 IPC Think Tank convened more than 100 specialists in psoriasis and industry partners from all over the world to discuss the most pressing issues affecting psoriasis care and treatment globally. The outcome of these discussions will inform IPC initiatives in 2021 and beyond.

Recently, the Task Force (TF) of the National Psoriasis Foundation (NPF) released a revised version of its COVID-19 statement after an in-depth analysis of publicly available data with two currently approved anti-SARS-CoV-2 vaccines in the US, both mRNA-based.